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Edited by Barry HalliwellAbstract Mutations in the parkin gene encoding an E3 ligase
are responsible for autosomal recessive Parkinsons disease.
Putative parkin substrates and interacting partners have been
identiﬁed, but the molecular mechanism underlying parkin-re-
lated neurodegeneration is still unclear. We have identiﬁed the
20S proteasomal subunit a4 (synonyms: PSMA7, XAPC7, sub-
unit alpha type 7) as a new interacting partner of parkin. The C-
terminal IBR-RING domain of parkin and the C-terminal part
of a4 were essential for the interaction. Biochemical studies re-
vealed that a4 was not a substrate for parkin-dependent ubiqui-
tylation. Putative functions of the interaction might therefore be
substrate presentation to the proteasome or regulation of prote-
asomal activity. Full-length parkin and parkin lacking the N-
terminal ubiquitin-like domain slightly increased the proteasomal
activity in HEK 293T cells, in line with the latter hypothesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinsons disease (PD) is a common neurodegenerative
disorder aﬀecting approximately 1–2% of the population over
60 years of age. It is characterized by resting tremor, rigidity
and bradykinesia caused by progressive degeneration of dopa-
minergic neurons in the substantia nigra pars compacta.
Although the majority of PD cases are sporadic, mutations
in several genes have been linked to familial forms of PD [1].
Among those, parkin mutations are responsible for up to
50% of hereditary, autosomal recessive, early onset PD cases,
characterized by early manifestation, relatively slow progres-
sion, and a good long-term response to levodopa therapy [2].
The parkin gene possesses 12 exons encoding 465 amino
acids. The protein is composed of a ubiquitin-like (UBL) do-*Corresponding author. Fax: +49 89 7095 3677.
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doi:10.1016/j.febslet.2005.06.003main at the N-terminus, followed by an in-between RING re-
gion (IBR) and two RING-ﬁnger domains at the C-terminus
[3] (Fig. 1A). Parkin has E3 ubiquitin-protein ligase activity
[4], and conjugates activated ubiquitin to proteins for further
degradation by the 26S proteasome. Known interacting
partners, which also serve as substrates for parkin-mediated
ubiquitylation, include CDCrel, synphilin, the Pael-receptor,
an O-glycosylated form of a-synuclein, the p38 subunit of
the aminoacyl-tRNA synthetase complex, synaptogamin XI
and tubulin (for reviews see [5] and [6]). These highly divergent
ubiquitylation substrates do not evoke, however, a unifying
cellular response. Thus, the exact mechanism by which parkin
plays a role in cell survival, homeostasis, intracellular inclusion
formation and neuroprotection remains to be elucidated.
In order to shed more light on the function of parkin, we
performed yeast two-hybrid (Y2H) screens to ﬁnd new interac-
tors and to link the protein to intracellular pathways.2. Materials and methods
2.1. Yeast-two-hybrid screen
cDNAs encoding full-length (FL) parkin and the parkin mutants
C289G, C418R were subcloned into the two-hybrid vector
pBTM116-D9 and used as baits to screen a human fetal brain cDNA
library (Clontech). The screening procedure was performed according
to [7]. Brieﬂy, the plasmids encoding parkin and its mutants were
transformed into the L40ccua yeast strain, tested for the absence of re-
porter gene activity, and co-transformed with a human fetal brain
cDNA library, subcloned into pACT2. For each transformation,
1 · 106 independent transformants were plated onto minimal medium
lacking amino acids Trp, Leu, His, and Ura (SD4 medium) and incu-
bated at 30 C for 5–10 days. Clones were picked into microtiter plates,
grown overnight in liquid minimal medium lacking Trp and Leu (SD2
medium) and spotted onto nylon membranes placed on SD4 agar
plates. The membranes were subjected to a b-galactosidase (b-GAL)
assay after 4 days of incubation. Plasmids obtained from positive
clones were sequence veriﬁed. For interaction mapping the assays were
performed with plasmids encoding baits and preys co-transformed into
L40ccua strain and plated onto SD4 medium. The eﬃciency of co-
transformations was tested on SD2 selective medium. The membranes
were subjected to a b-GAL assay as above.
2.2. Cell culture
PC12 cells, stably transfected to express FL human parkin under
the control of the tetracyclin-dependent Tet-oﬀ promotor (Clontech),
were maintained in Dulbeccos modiﬁed Eagles medium containing
0.11 g/l sodium-pyruvate, pyridoxine (Gibco), 10% horse serum, 5%blished by Elsevier B.V. All rights reserved.
Fig. 1. The proteasomal subunit a4 interacts with parkin in the Y2H assay. (A) Parkin protein structure and bait constructs used for human fetal
brain cDNA library and interaction mapping Y2H screens. The black boxes represent parkin with mutations at positions C289G and C418R. (B)
Results from reporter activity assay. Parkin C-terminal baits, which activated the HIS3, URA3 (SD4 minimal plates) and lacZ reporter genes
(membranes) after co-transformation with empty pACT2 vector in the L40ccua strain, were excluded from further interaction mapping analysis. The
membranes were spotted using 2 · 2 patterns. (C) The interaction between FL parkin and a C-terminal fragment of the proteasome subunit a4 (aa
179–248) could be conﬁrmed in an independent co-transformation assay. UBL, ubiquitin-like; IBR, in-between-RING; FL, Full-length; NT,
N-terminal; CT, C-terminal.
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mine (Gibco), penicillin/streptomycin (Invitrogen, 100 units/ml and
100 lg/ml, respectively), and 100 lg/ml geneticin (Gibco) at 37 C, in
a chamber containing 5% CO2. Hygromycin B and doxycycline, a tet-
racyclin analogue, were added to maintain stable transfection and sup-
press parkin expression.
HEK 293 and HEK 293T cells were cultivated in Dulbeccos MEM
with addition of Glutamax 1, sodium pyruvate, 4500 mg/l glucose, pyr-
idoxine (Gibco), penicillin/streptomycin (100 units/ml and 100 lg/ml,
respectively) and 10% fetal calf serum. To maintain stable transfection,
HEK 293 cells stably overexpressing parkin were supplemented with
Zeocin (Invitrogen) (200 lg/ml).
2.3. Plasmids
The Y2H vectors pACT2 and pBTM116D-9 were described earlier
[7]. The cDNA fragment encoding the FL a4 isoform 1 was ampliﬁed
by PCR (based on NCBI_NM002792 accession number) from a mouse
brain cDNA library and subcloned into pFLAG-CMV-2 (Sigma). The
cDNAs encoding the last 70 amino acids of human a4 (aa 179–248)
were subcloned downstream of the HA-tag into the pTL1-HA-D48
vector. Delta-UBL parkin was subcloned downstream of the HA-taginto the HA-pcDNA3 vector, as described elsewhere [8,9]. The plas-
mids for the expression of the truncated parkin fragments HA-
parkin(1–191) and HA-parkin(192–465) were generated by subcloning
of cDNA fragments into pTL1-HA1-D48. MYC-tagged parkin pro-
teins (FL, aa 1–144 and aa 294–465) were produced by expression of
subcloned cDNA fragments with pcDNA3.1 zeo(-) [10]. All constructs
were sequence veriﬁed. The plasmids for the expression of FLAG-
tagged parkin (N-FLAG-pcDNA3), HA-CDCrel (pRK-5-HA), and
p6HIS-ubiquitin (pMT107) were kindly provided by R. Takahashi,
T. Dawson and G. Bossis, respectively.2.4. Co-immunoprecipitation assays
Tet-oﬀ PC12 cells were transfected with Lipofectamine 2000, as rec-
ommended by the manufacturers instructions. Two days after trans-
fection, the cells were harvested, washed with cold PBS and lysed in
50 mM Tris–HCl, 200 mMNaCl, 0.5% Nonidet 40 and protease inhib-
itors (Complete Mini, Roche). Cell lysates were then rotated at 4 C
for 30 min and centrifuged for 10 min, at 5000 · g. The protein concen-
tration of the supernatant was determined using the BCA Protein
Assay Reagent Kit (Pierce). HEK 293 cells, which were more sensitive
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mapping experiments in PC12 cells, 5 lg of puriﬁed human 20S protea-
some (Biotrend) was added to 300 lg of cell lysate proteins.
Equal amounts of total protein were incubated with EZviewe Red
Anti-FLAG M2 Aﬃnity Gel (Sigma) or agarose-immobilized mouse
monoclonal antibodies (Abs) to 20S proteasome subunit a4 (Biotrend),
previously equilibrated in TBS, for 3–6 h at 4 C. After centrifugation
the beads were washed with TBS. Precipitates were eluted with loading
buﬀer and denatured for 5 min at 95 C. The precipitated proteins were
separated by SDS–PAGE and transferred to PVDF membranes.
Immunolabeling was performed with anti-FLAG M2 monoclonal
Abs (Sigma), anti-Parkin polyclonal Abs (Cell Signaling, recognizing
an epitope around aa 400 of parkin), anti-HA monoclonal Abs (clone
16B12, BabCo) and monoclonal Abs against the proteasomal subunits
a4, b7 and Rpt3 (Biotrend), followed by incubation with the appropri-
ate secondary antibody conjugated to horseradish peroxidase (Dako).
The protein bands were visualized with the Lumi-light substrate
(Roche).
2.5. Ubiquitylation assays
Native or HEK 293 cells stably overexpressing parkin were transfec-
ted with His-ubiquitin, HA-CDCrel and FLAG-a4. Twenty-four hours
after transfection, the cells were treated for 8 h with 1 lM epoxomicin
(Sigma) to block proteasomal activity. Cells were then lysed in 50 mM
Tris–HCl, 200 mM NaCl, pH 7.5 buﬀer, containing 0.5% Nonidet 40
and protease inhibitors. Immunoprecipitation was performed, as
above, with a monoclonal anti-HA agarose conjugate for HA-CDCrel
or EZviewe Red Anti-FLAG M2 Aﬃnity Gel for FLAG-a4 (both
from Sigma). The immunoprecipitates and cell lysates were analysed
by Western blot with anti-HA (High Aﬃnity, Roche), anti-FLAG
M5 monoclonal (Sigma) and antiHis-PentaHis (Qiagen) Abs.
2.6. Proteasomal activity assay
HEK 293T cells were transiently transfected with MYC-FL par-
kin and HA-delta UBL parkin. Cells were scraped into 25 mM
Tris–HCl buﬀer, pH 7.5 and lysed on ice. After centrifugation
at 4 C, the supernatant was diluted with lysis buﬀer to a concen-
tration of 20 lg/200 ll (ﬁnal volume). The following substrates
were added to obtain a ﬁnal concentration of 20 lM, for chymo-
trypsin-like activity: Suc-LLVY-AMC, for trypsin-like activity:
Boc-LRR-AMC, for PGPH-like activity: Z-LLE-AMC (all from
Calbiochem). The increase of ﬂuorescence was monitored at 120
time points during 1 h. The experiments were repeated four times.
The values were normalized to the activity of the empty
pcDNA3.1 vector. The increase of activity is presented in per-
cent ± 95% conﬁdence interval (CI).3. Results
3.1. The C-terminus of the 20S proteasomal subunit a4 interacts
with the C-terminus of parkin
To identify novel parkin interaction partners, we per-
formed Y2H screens of a human fetal cDNA brain library
using FL wild-type parkin as well as the FL parkin mutants
(C289G, C418R) as baits (Fig. 1A). This led to the isolation
of a 540 bp cDNA clone encoding the last 70 amino acids (aa
179–248) of the proteasome subunit a4 (NCBI: NM_002792),
a component of the 20S proteasome. The interaction between
parkin and a4 was speciﬁc, as parkin failed to interact with
the unrelated protein v-HA-Ras or the control proteins
HIP1 and SH3GL3 ([7], data not shown). To determine the
protein domains required for the interaction between parkin
and a4, truncated fragments of both proteins were analysed
by two-hybrid co-transformation assays. We found that the
C-terminal parkin fragments with the RING domains auto-
activated the HIS3, URA3 and lacZ reporter genes in the
L40ccua strain, while FL parkin or an N-terminal fragment
(aa 1–191) did not (Fig. 1B). Thus, the C-terminal parkinfragments (aa 192–465) could not be used for mapping of
the binding region using the Y2H system. However, further
two-hybrid studies revealed that, in contrast to FL parkin,
the N-terminal parkin fragment (aa 1–191) did not interact
with the C-terminal a4 fragment (Fig. 1C), suggesting that
the binding region is located in the C-terminal part of parkin.
Since due to autocativation an association of a4 with
the C-terminus of parkin could not be examined in the
Y2H assay, we also performed binding assays with both
proteins using biochemical methods. We ﬁrst performed
co-immunoprecipitation experiments in PC12 cells stably
overexpressing parkin with a tetracyclin-dependent Tet-oﬀ
promotor. In addition, FLAG-tagged a4 was transiently
overexpressed in these cells (Fig. 2A). Both overexpressed
and endogenous parkin were detected in FLAG-a4 immu-
noprecipitates (Fig. 2A, left panel). The interaction was
also seen in the opposite direction when FLAG-parkin
was precipitated from HEK 293 cells co-transfected with
HA-C-terminal a4 (Fig. 2B). This experiment conﬁrmed
that aa 179–248 of a4 contain the parkin-interaction do-
main. FLAG-a4 was not integrated in the proteasome
(probably due to its N-terminal tag) since the b7 subunit
as part of the 20S complex could not be co-precipitated
under the same conditions (Fig. 2C). Therefore, an indirect
interaction via other 20S subunits seems unlikely.
In order to exclude experimental artefacts due to overex-
pression of a4, we immunoprecipitated endogenous a4 in
HEK 293 cells and could detect overexpressed FL parkin
(Fig. 3A, middle panel). This experiment also showed that
under the same experimental conditions other 20S subunits
(b7 as representative) could be co-precipitated whereas the
19S subunit Rpt3 was not (Fig. 3A, middle panel). This
demonstrates that parkin indeed interacts with the 20S pro-
teasome a in addition to the reported interaction with 19S
cap [11,12]. The absence of the 19S subunits in a4 immuno-
precipitations can most likely be explained by a dissociation
of the proteasome into its two major components (19S and
20S) during storage of the cell lysates for several days at
20 C. The direct interaction of parkin with the 20S pro-
teasome was further veriﬁed by a4-immunoprecipitation of
FL parkin with puriﬁed human 20S proteasome added to
transfected PC12 cell lysates (Fig. 3B). This experiment
was feasible because the monoclonal anti-a4 antibody recog-
nized and immunoprecipitated only the human 20S contain-
ing the a4-subunit. The use of rat cells (PC12) enabled us to
avoid cross-reactivity with the endogenous proteasome sub-
units, as shown in lanes 4 to 9 (detection with anti-a4
Abs, Fig. 3B).
The parkin C-terminus (aa 294–465) was suﬃcient for the
interaction (Fig. 3B, lane 3). This region of parkin encom-
passes the IBR-RING2 motif (Fig. 1A).
We also wanted to analyze co-localisation of the proteins by
immunocytochemistry, using the anti-parkin and anti-a4 Abs.
Since in HEK 293 and in SHSY-5Y cell lines parkin is ex-
pressed at relatively low levels, we were unable to demonstrate
a colocalisation of endogenous parkin with the a4 subunit.
However, when parkin was overexpressed, partial colocalisa-
tion with endogenous a4 was observed in the cytoplasm of
the HEK 293 cells (data not shown). Nevertheless, since both
proteins were diﬀusely localized in the cytoplasm, immuno-
cytochemistry was not the adequate method to support the
interaction.
Fig. 2. Veriﬁcation of the interaction of proteasomal subunit a4 with parkin by co-immunoprecipitation assays. (A) Endogenous parkin interacts
with FLAG-a4 in parkin-tet-oﬀ-PC12 cells (left panel, lane 2, and asterisk) as well as overexpressed parkin (left panel, lane 4). Right panel, loading
controls. Input (in all ﬁgures): lysates used for the immunoprecipitation. (B) The C-terminal part of a4 is responsible for the interaction with parkin.
HA-a4 (aa179–248) was co-immunoprecipitated with FLAG-Parkin in HEK 293 cells (lane 1). (C) b7 subunit of the proteasome was not co-
immunoprecipitated with transiently overexpressed FLAG-a4 in HEK 293 cells neither in the presence nor the absence of parkin (left panel, lane 5
and 7), showing that it is not incorporated in the proteasome. Right panels represent the loading controls. The IP-supernatant in the right panel
shows that FLAG-a4 could be almost completely precipitated.
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In order to evaluate the functional consequences of the
interaction between parkin and a4, we ﬁrst examined
whether a4 could serve as substrate for parkin, since many
of the previously identiﬁed parkin interactors are ubiquity-
lated by parkin due to its E3-ligase activity. We transiently
transfected FLAG-tagged a4 or HA-tagged CDCrel, actingas a positive control for the assay [13], together with HIS-
tagged ubiquitin in both native HEK 293 cells or HEK
293 cells stably overexpressing wild-type parkin. Proteasome
function was blocked with epoxomicin before immunopre-
cipitation, allowing ubiquitylated proteins to accumulate.
When ubiquitylated proteins were labelled in whole lysates
with anti-HIS antibody, no relevant diﬀerence in ubiquityla-
Fig. 3. Parkin associates with the 20S proteasome via its C-terminus. (A) Endogenous a4 co-precipitates FLAG-FL Parkin in HEK 293 cells
(detection anti-parkin). In addition, 20S subunits were co-precipitated (detection anti-b7, representing the 20S complex), but not the 19S subcomplex
(detection anti-Rpt3, representing the 19S complex). (B) Puriﬁed human 20S proteasome was added to PC12 lysates transiently overexpressing the
indicated parkin constructs. The 20S subunit was precipitated by anti-a4 Abs and co-precipitated both FL- and N-terminally truncated parkin (lanes
1–3).
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input lanes in both panels). CDCrel immunoprecipitates,
however, contained high molecular weight proteins corre-
sponding to ubiquitylated CDCrel that were more abundant
in HEK 293 cells that overexpressed parkin than in thosethat did not (Fig. 4A, left panel). No such diﬀerences were
detected in immunoprecipitates of a4 (Fig. 4A, right panel).
When CDCrel and a4 precipitates were visualized by the
respective anti-tag Abs, CDCrel showed parkin-dependent
ladder formation as a sign for ubiquitylation whereas a4
Fig. 4. Alpha-4 is not ubiquitylated by parkin. Ubiquitylation of a4 by parkin was tested in native HEK 293 cells or HEK 293 cells stably
overexpressing parkin. The cells were transiently transfected with the indicated vectors followed by immunoprecipitation with anti-HA (for CDCrel)
or anti-FLAG Abs (for a4). (A) Immunolabeling for ubiquitinated proteins was performed with anti-HIS Abs. CDCrel served as a substrate for
parkin-dependent ubiquitinylation (left panel, lane 1 vs. 2), whereas a4 did not (right panel, lanes 1 vs. 2). (B) Immunolabeling for CDCrel and a4
was performed with anti-HA and anti-FLAG Abs, respectively. In the case of CDCrel, parkin-dependent ladder formation, i.e. ubiquitylation, was
observed (left panel, lane 1 vs. 2 and lane 3 vs. 4), which was not the case for the a4 proteasomal subunit (right panel, lane 1 vs. 2). Lanes 3 and 4 are
loading controls. Representative results of three independent experiments are presented.
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parkin-dependent ubiquitylation.3.3. Parkin inﬂuences proteasomal activity via its C-terminus
We therefore examined whether parkin inﬂuences proteaso-
mal activity, because a4 has a gating function on proteasomal
activity [14] (see Section 4). In HEK 293T cells, overexpression
of FL parkin caused – in comparison to the empty vector – a
small but signiﬁcant increase in chymotrypsin (CT)-like and
PGPH-like activity (8.6 ± 6.3% and 8.4 ± 8.2%, respectively).
The increase of trypsin (T)-like activity did not reach signiﬁ-
cance (5.6 ± 10.4%). The increase of activity was accentuated
when parkin lacking the UBL domain was overexpressed:CT-like 10.7 ± 2.3%, PGPH-like 11.1 ± 8.2% and T-like
13.5 ± 6.0%.4. Discussion
We have identiﬁed the a4-subunit of the 20S proteasome
as a novel parkin interactor. This ﬁnding is intriguing
since several other E3 ubiquitin ligases and proteins con-
taining a UBL domain have recently been reported to
interact with the 19S regulatory part (cap) of the protea-
some [15]. Noticeably, interactions between parkin and
the Rpn10 [11] and Rpt6 [12] subunits of the 19S cap
have been described.
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that parkin also interacts with the 20S proteasome (core). We
hypothesize that the interaction must be of a weak and/or tran-
sient nature, since we were not able to detect the 26S or 20S pro-
teasome after immunoprecipitating the overexpressed parkin.
Sakata et al. [11] might have faced the same problem. They only
reported co-precipitation of parkin with the proteasome. A co-
precipitation in the opposite direction was not described. In
the present study, the co-precipitation of endogenous parkin
with the proteasome was unsuccessful, since the endogenous
parkin levels were too low in the human cell lines used (HEK
293 and SHSY-5Y), as well as in brain lysates.
The interactionbetweenparkinanda4mayhave several impli-
cations. Unlike the majority of many other proteins interacting
with parkin, e.g. CDCrel, a4 was not ubiquitylated in a parkin-
dependent manner, showing that a4 is not a parkin substrate.
As generally postulated for proteins transiently associated
with the 26S proteasome [15,11], parkin might mediate the sub-
strate presentation to the proteasome. The exact mechanism of
substrate presentation is currently unknown, but parkin, like
other proteins with UBL-domains, may recruit additional fac-
tors to the degradation machinery [12]. Tsai et al. described a
complex containing parkin, HSP70, a protein with an expanded
polyglutamine tract and the proteasome, which may be impor-
tant for the elimination of the polyglutamine-containing protein
[12]. It has also been hypothesized that parkin, a polyubiquity-
lated substrate and other subunits of the 19S regulatory com-
plex, like Rpn1 or Rpn2, might transiently interact to form a
platform which eﬃciently ubiquitylates proteins and targets
them for degradation to the proteasome [15]. In these studies,
the UBL-domain of parkin and the 19S regulatory complex of
the 26S proteasome were of particular importance. In light
of the presented novel interaction, it could be speculated that
also the 20S proteasome plays a role in parkin-mediated sub-
strate presentation to the proteasome.
Another hypothesis would be that parkin inﬂuences proteaso-
mal activity via its interaction with a4. Because of the X-ray
structure of the yeast proteasome, in which the C-terminus of
a4 protrudes into the solvent, it has been suggested that a4
may interact with regulatory factors [16]. The N-terminus of
a4 protrudes towards the lumenof the proteasome, having a gat-
ing function [14]. Interestingly, modulation of protein turnover
was postulated for the hepatitis B virus X protein (HBX), which
also interacts with a4 and, like parkin, is a substrate of the pro-
teasome [17]. Downregulation of parkin by anti-sense technol-
ogy decreased the degradation of the artiﬁcial proteasome
substrate GFP-CL1 which is not a parkin substrate [18], sup-
porting the hypothesis that parkin inﬂuences proteasomal activ-
ity. Our data show that parkin overexpression slightly enhances
proteasomal activity, which is in agreement with other studies
[19]. The increase was even stronger for parkin lacking the
UBL-domain (delta-UBL). This points to an interaction with
the 20S proteasome, because the UBL-domain of parkin is
known to associate with the 19S regulatory cap [11]. Finally,
all three proteasomal activities were inﬂuenced by delta-UBL
parkinwhich is in linewith our idea that parkin regulates the gat-
ing function of a4. The selective loss of a-subunits and concom-
itant reduction of proteasomal activity in the substantia nigra
pars compacta of PD patients [20] is intriguing in this context.
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